UK Regulator ‘Optimistic’ About EU Proposals For Northern Ireland Drug Supply
MHRA Fields Tricky Post-Brexit Regulatory Questions
Executive Summary
Among the many problems thrown up by Brexit is how to deal with situations where an innovative product that falls within the scope of the EU centralized procedure is filed in Great Britain but not in the EU, potentially denying access to the medicine in Northern Ireland. A recent webinar saw officials from the UK regulator explain the new rules on medicines supply between GB and NI.
You may also be interested in...
Navigating The UK's Post-Brexit Regulatory Complexities
The UK regulator explains the new requirements for batch testing and release in Great Britain and Northern Ireland, what's involved in importing clinical trial drugs to Northern Ireland, and what factors determine the location of the Qualified Person.
EU Proposes Unilateral Solution To Northern Ireland Medicines Supply Problems
The latest proposals for solving regulatory and trade issues caused by Brexit and the Northern Ireland Protocol have been welcomed by EU and UK pharmaceutical industry bodies.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.